Abstract:
BACKGROUND:Prednisolone is a potent anti-inflammatory glucocorticoid (GC) but chronic use is hampered by metabolic side effects. Little is known about the long-term effects of GCs on gene-expression in vivo during inflammation. AIM:Identify gene signatures underlying prednisolone-induced metabolic side effects in a complex in vivo inflammatory setting after long-term treatment. MATERIALS & METHODS:We performed whole-genome expression profiling in liver and muscle from arthritic and nonarthritic mice treated with several doses of prednisolone for 3 weeks and used text-mining to link gene signatures to metabolic pathways. RESULTS:Prednisolone-induced gene signatures were highly tissue specific. We identified a short-list of genes significantly affected by both prednisolone and inflammation in liver and involved in glucose and fatty acid metabolism. For several of these genes the association with GCs is novel. CONCLUSION:The identified gene signatures may provide useful starting points for the development of GCs with a better safety profile.
journal_name
Pharmacogenomicsjournal_title
Pharmacogenomicsauthors
Ellero-Simatos S,Fleuren WW,Bauerschmidt S,Dokter WH,Toonen EJdoi
10.2217/pgs.14.3subject
Has Abstractpub_date
2014-04-01 00:00:00pages
629-41issue
5eissn
1462-2416issn
1744-8042journal_volume
15pub_type
杂志文章相关文献
PHARMACOGENOMICS文献大全abstract:AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.17
更新日期:2010-05-01 00:00:00
abstract:AIMS:The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated co...
journal_title:Pharmacogenomics
pub_type: 临床试验,杂志文章
doi:10.2217/pgs.10.51
更新日期:2010-06-01 00:00:00
abstract::Biobanking became a necessity for translating genetic discoveries into clinical practice. Approaches to personalized medicine require a new model system for functional and pharmacogenomic studies of a variety of accumulating genetic variations, as well as new research environments such as biobankomics. Human lymphobla...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.11.24
更新日期:2011-06-01 00:00:00
abstract:AIM:This study aimed to investigate the effect of CYP3A4 and CYP3A5 genotypes on clinical outcomes of docetaxel treatment. PATIENTS & METHODS:In the PROMIX trial, 150 breast cancer patients received docetaxel preoperatively. CYP3A4 and CYP3A5 genotype combinations were transformed into total CYP 3A phenotypes. RESULT...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2018-0080
更新日期:2018-11-01 00:00:00
abstract::The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...
journal_title:Pharmacogenomics
pub_type: 杂志文章,多中心研究,评审
doi:10.2217/pgs.12.159
更新日期:2012-11-01 00:00:00
abstract::Recent years have seen great advances in our understanding of genetic contributors to drug response. Drug discovery and development around targeted genetic (somatic) mutations has led to a number of new drugs with genetic indications, particularly for the treatment of cancers. Our knowledge of genetic contributors to ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.13.52
更新日期:2013-05-01 00:00:00
abstract:AIM:In order to administer antipsychotic medication with the most beneficial outcome, the appropriate drug and dose needs to be identified. Though often not considered in pharmacogenetic studies, dosage plays an important role in treatment outcome. This study set out to analyze the association between 109 SNPs and anti...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.171
更新日期:2016-02-01 00:00:00
abstract:AIM:To investigate the pharmacokinetics of voriconazole when administered to HIV-positive patients receiving treatment with atazanavir-containing therapies according to CYP2C19 genotype. MATERIALS & METHODS:We describe four HIV-positive patients with pulmonary aspergillosis treated with voriconazole and atazanavir-bas...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.92
更新日期:2014-07-01 00:00:00
abstract::The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.5.651
更新日期:2002-09-01 00:00:00
abstract::Multiple sclerosis (MS) is a condition of the CNS marked by inflammation and neurodegeneration. Interferon (IFN)-beta was the first, and still is the main, immunomodulatory treatment for MS. Its clinical efficacy is limited, and a proportion of patients, ranging between 20-55%, do not respond to the therapy. Identific...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.10.108
更新日期:2010-08-01 00:00:00
abstract::While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.12.1
更新日期:2012-03-01 00:00:00
abstract::Drugs used to treat psychiatric disorders, even when taken as directed, fail to provide adequate relief for a sizeable proportion of patients. Despite our advancements in understanding human genetics and development of high-throughput tools to probe variation, pharmacogenomics has yielded marginal ability to predict d...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2017-0104
更新日期:2017-10-01 00:00:00
abstract:AIM:Hemoglobinopathies exhibit a remarkable phenotypic diversity that restricts any safe association between molecular pathology and clinical outcomes. PATIENTS & METHODS:Herein, we explored the role of genes involved in the nitric oxide biosynthesis and signaling pathway, implicated in the increase of fetal hemoglobi...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.16.1
更新日期:2016-03-01 00:00:00
abstract::COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical co...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2020-0048
更新日期:2020-07-01 00:00:00
abstract::Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2017-0020
更新日期:2017-06-01 00:00:00
abstract::After a 1-day advanced course on systems biology, the main themes of this 3-day colloquium were developed: from systems biology to systems medicine with special applications to cancer; pharmacogenomics in drug discovery and clinical application; and epigenomics and genome-wide association studies in cardiovascular dis...
journal_title:Pharmacogenomics
pub_type:
doi:10.2217/pgs.13.201
更新日期:2013-12-01 00:00:00
abstract::Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.12.113
更新日期:2012-09-01 00:00:00
abstract::EVALUATION OF: Ahuja SK, Kulkarni H, Catano G et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008). It is widely accepted that the effect of highly active antiretroviral therapy (HAART) varies widely among HIV...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.9.9.1347
更新日期:2008-09-01 00:00:00
abstract::Human cytochrome P450 (CYP)3A is a major P450 enzyme found in the liver and gastrointestinal tract. It plays an important role in the metabolism of a wide variety of drugs, some endogenous steroids and harmful environmental contaminants. It has been shown that CYP3A alleles encoding enzymes with little or no activity ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.6.7.731
更新日期:2005-10-01 00:00:00
abstract::Pharmacogenomics seeks to understand the genetic basis of interindividual differences in drug disposition and effects. Differential drug response is likely to most often be a complex trait, in which multiple genes contribute with varying strengths to the therapeutic phenotype. Due to technical and economic limitations...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.6.781
更新日期:2002-11-01 00:00:00
abstract:AIM:Tamoxifen is one of the most commonly used endocrine therapeutic agents for breast cancer. Although many studies have examined whether the treatment outcomes of tamoxifen for breast cancer differ according to CYP2D6 genotype, the study results have been inconsistent, and the role of CYP2D6 in the prediction of pati...
journal_title:Pharmacogenomics
pub_type: 杂志文章,meta分析
doi:10.2217/pgs.13.221
更新日期:2014-01-01 00:00:00
abstract:AIM:The present study explored the integrative effect of genes encoding methadone pharmacokinetic and pharmacodynamic pathways on methadone maintenance doses in Han Chinese Patients. MATERIALS & METHODS:Genomic DNA was extracted from 321 opioid-dependent patients and 202 healthy controls, and realtime-PCR and PCR-RFLP...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.11.96
更新日期:2011-11-01 00:00:00
abstract:AIM:A population pharmacokinetic (PPK) analysis was conducted to describe the influence of GSTA1 polymorphisms on intravenous busulfan in adults undergoing allogeneic hematopoietic stem cell transplantation. PATIENTS & METHODS:A PPK model was developed from 36 patients by a one-compartment model with first-order elimi...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.98
更新日期:2015-01-01 00:00:00
abstract:AIMS:To determine the extent of pharmacogenomics instruction at US and Canadian medical schools, characterize perceptions of curricular coverage, identify curricular resources and compare responses with similar studies conducted in US pharmacy schools and British medical schools. MATERIALS & METHODS:A survey was sent ...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.122
更新日期:2010-09-01 00:00:00
abstract::Aim: The CYP2D6 gene is highly polymorphic and harbors population specific alleles that define its predominant metabolizer phenotype. This study aimed to identify polymorphisms in Indian population owing to scarcity of CYP2D6 data in this population. Materials & methods: The CYP2D6 gene was resequenced in 105 south In...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2019-0049
更新日期:2019-07-01 00:00:00
abstract:INTRODUCTION:Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase and folate-dependent enzymes. Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and has been shown to be polymorphic, affecting the enzyme activity. METHODS:To examine...
journal_title:Pharmacogenomics
pub_type: 临床试验,杂志文章
doi:10.2217/14622416.8.11.1551
更新日期:2007-11-01 00:00:00
abstract::Large differences are observed in chemotherapy response between breast cancer patients, with a substantial part of this variability being explained by genetic factors. Polymorphisms in genes encoding drug-metabolizing enzymes, drug transporters and drug targets influence the pharmacokinetics and pharmacodynamics of th...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.12.44
更新日期:2012-04-01 00:00:00
abstract::The second Annual Meeting of the UK Pharmacogenetics and Stratified Medicine Network was held on 28 September 2011 at The Wellcome Trust Conference Centre on the Wellcome Trust Genome Campus at Hinxton, Cambridge, UK. The meeting preceded the annual Pharmacogenomics and Personalized Medicine conference, which was held...
journal_title:Pharmacogenomics
pub_type:
doi:10.2217/pgs.11.162
更新日期:2012-01-01 00:00:00
abstract:AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.58
更新日期:2015-01-01 00:00:00
abstract::The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. Pharmacogenomics-base...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.14.144
更新日期:2014-12-01 00:00:00